Search results for "1306 Cancer Research"

showing 10 items of 21 documents

Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signaling

2017

The pathogenesis of chronic lymphocytic leukemia (CLL) has been linked to constitutive NF-κB activation but the underlying mechanisms are poorly understood. Here we show that alternative splicing of the negative regulator of NF-κB and tumor suppressor gene CYLD regulates the pool of CD5+ B cells through sustained canonical NF-κB signaling. Reinforced canonical NF-κB activity leads to the development of B1 cell-associated tumor formation in aging mice by promoting survival and proliferation of CD5+ B cells, highly reminiscent of human B-CLL. We show that a substantial number of CLL patient samples express sCYLD, strongly implicating a role for it in human B-CLL. We propose that our new CLL-l…

0301 basic medicineCancer ResearchTumor suppressor geneCell SurvivalRNA SplicingChronic lymphocytic leukemia2720 Hematology610 Medicine & healthBiologyCD5 Antigenslaw.inventionPathogenesisMice03 medical and health sciencesimmune system diseaseslawhemic and lymphatic diseasesmedicineAnimalsHumans10239 Institute of Laboratory Animal Science1306 Cancer ResearchGenes Tumor SuppressorGeneCell ProliferationB-LymphocytesAlternative splicingNF-kappa BUbiquitinationHematologymedicine.diseaseLeukemia Lymphocytic Chronic B-CellDeubiquitinating Enzyme CYLDLeukemia030104 developmental biologyOncologyImmunologyCancer research570 Life sciences; biologySuppressor2730 OncologyCD5Signal TransductionLeukemia
researchProduct

IL-17A mediated endothelial breach promotes metastasis formation

2015

Abstract The role of the IL23/IL17A axis in tumor–immune interactions is a matter of controversy. Although some suggest that IL17A-producing T cells (TH17) can suppress tumor growth, others report that IL17A and IL23 accelerate tumor growth. Here, we systematically assessed the impact of IL17A-secreting lymphocytes in several murine models of tumor lung metastasis. Genetic fate mapping revealed that IL17A was secreted within lung metastases predominantly by γδ T cells, whereas TH17 cells were virtually absent. Using different tumor models, we found Il17a−/− mice to consistently develop fewer pulmonary tumor colonies. IL17A specifically increased blood vessel permeability and the expression …

0301 basic medicineGenetically modified mouseCancer ResearchPathologymedicine.medical_specialtyLung NeoplasmsEndotheliumImmunologyMelanoma ExperimentalVascular permeability610 Medicine & healthBiology10263 Institute of Experimental ImmunologyCapillary Permeability03 medical and health sciencesCarcinoma Lewis LungCell Line TumormedicineCell AdhesionAnimals1306 Cancer ResearchCell adhesionMice Knockout2403 ImmunologyLungMelanomaInterleukin-17Transendothelial and Transepithelial MigrationEndothelial Cellsmedicine.diseaseMice Inbred C57BL030104 developmental biologymedicine.anatomical_structureCell culture570 Life sciences; biologyInterleukin 17Endothelium VascularNeoplasm Transplantation
researchProduct

Ectopic myoglobin expression is associated with a favourable outcome in head and neck squamous cell carcinoma patients

2016

BACKGROUND/AIM: Ectopic myoglobin (MB) expression, mediated by alternative and hypoxia-inducible transcription, has recently been demonstrated in several epithelial tumours. This study aimed to examine the expression of MB in hormone-independent head and neck squamous cell carcinomas (HNSCCs). PATIENTS AND METHODS: Using imunohistochemistry, ectopic MB expression was analyzed on tissue microarrays (TMAs) of 524 patients with localized and locally advanced primary and recurrent HNSCC who had undergone surgical treatment with curative intent. Associations of MB expression with survival and clinicopathological parameters were analyzed. RESULTS: MB expression was found in 45.8% of HNSCC patient…

0301 basic medicineOncologyMaleCancer ResearchPathologyCellMedizinchemistry.chemical_compound0302 clinical medicineMedicine1306 Cancer ResearchHead and neckSurgical treatmentChildTissue microarrayMyoglobinHazard ratioGeneral MedicineMiddle Aged10081 Institute of Veterinary Physiologymedicine.anatomical_structureTreatment OutcomeOncologyMyoglobinHead and Neck Neoplasms030220 oncology & carcinogenesisChild PreschoolCarcinoma Squamous CellFemale2730 OncologyAdultmedicine.medical_specialtyHPVAdolescenthead and neck squamous cell carcinoma03 medical and health sciencesYoung AdultInternal medicineHumansbusiness.industryInfant NewbornInfantmedicine.diseaseHead and neck squamous-cell carcinomaConfidence interval030104 developmental biologychemistry570 Life sciences; biologyprognosisbusiness
researchProduct

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafen…

2020

Abstract Background BRAF/MEK inhibitor combinations are established treatments for BRAF V600–mutant melanoma based on demonstrated benefits on progression-free survival (PFS) and overall survival (OS). Here, we report an updated analysis of the COLUMBUS (COmbined LGX818 [encorafenib] Used with MEK162 [binimetinib] in BRAF mutant Unresectable Skin cancer) trial with long-term follow-up. Methods In part 1 of the COLUMBUS trial, 577 patients with advanced/metastatic BRAF V600–mutant melanoma, untreated or progressed after first-line immunotherapy, were randomised 1:1:1 to 450 mg of encorafenib QD + 45 mg of binimetinib BID (COMBO450) vs 960 mg of vemurafenib BID (VEM) or 300 mg of encorafenib …

0301 basic medicineOncologyMaleCancer ResearchSkin NeoplasmsMedizinchemistry.chemical_compound0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsOutcome Assessment Health CareMedicine1306 Cancer ResearchVemurafenibMelanomaAged 80 and overSulfonamidesMEK inhibitorMelanomaHazard ratio10177 Dermatology ClinicBinimetinibNauseaMiddle AgedPrognosisOncologyTolerability030220 oncology & carcinogenesis2730 OncologyFemalemedicine.drugAdultDiarrheaProto-Oncogene Proteins B-rafmedicine.medical_specialtyVomiting610 Medicine & healthDisease-Free Survival03 medical and health sciencesInternal medicineHumansneoplasmsAgedbusiness.industrymedicine.diseaseConfidence interval030104 developmental biologychemistryVemurafenibMutationBenzimidazolesCarbamatesSkin cancerbusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with Ovarian or Testicular Germ Cell Tumors; Data of the…

2020

Objective: To evaluate prognostic factors in pediatric patients with gonadal germ cell tumors (GCT). Methods: Patients <18 years with ovarian and testicular GCT (respectively OGCT and TGCT) were prospectively registered according to the guidelines of MAKEI 96. After resection of the primary tumor, patients staged ≥II received risk-stratified cisplatin-based combination chemotherapy. Patients were analyzed in respect to age (six age groups divided into 3-year intervals), histology, stage, and therapy. The primary end point was overall survival. Results: Between January 1996 and March 2016, the following patients were registered: 1047 OGCT, of those, 630 had ovarian teratoma (OTER) and 417…

0301 basic medicineOncologyendocrine systemCancer Researchmedicine.medical_specialtymedicine.medical_treatment610 Medicine & healthOvarytestisBiologyHistogenesislcsh:RC254-282Articlehistology03 medical and health sciences0302 clinical medicineInternal medicinemedicinesex1306 Cancer Researchddc:610Ovarian Teratomagerm cell tumorsStage (cooking)Combination chemotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePrimary tumor030104 developmental biologymedicine.anatomical_structurechildren and adolescentsageOncology10036 Medical Clinic030220 oncology & carcinogenesis2730 OncologyovaryGerm cell tumorsWatchful waitingCancers
researchProduct

Glutathione S-transferase T1 and M1 gene defects in ovarian carcinoma

1998

Glutathione S-transferases (GSTs) M1 and T1 are known to be polymorphic in humans. Both polymorphisms are due to gene deletions, which are responsible for the existence of null genotypes. The gene defect of GSTT1 has been reported to be associated with an increased risk of myelodysplastic syndromes, astrocytoma and meningioma. A lack of GSTM1 was associated with tobacco smoke-induced lung and bladder cancer. In this study we examined whether the GSTT1 and/or GSTM1 homozygous null genotypes were associated with an increased risk of ovarian cancer using a multiplex polymerase chain reaction protocol. The GSTT1 null genotype was observed in 14% of the control subjects that had never suffered f…

AdultGenetic MarkersCancer Researchmedicine.medical_specialty10050 Institute of Pharmacology and Toxicology610 Medicine & healthGastroenterologyInternal medicineOvarian carcinomaGenotypemedicineCarcinomaHumans1306 Cancer ResearchFamily historyneoplasmsAgedGlutathione TransferaseAged 80 and overOvarian NeoplasmsPolymorphism GeneticBladder cancerbiologyAge FactorsAstrocytomaMiddle Agedmedicine.diseaseNeoplasm ProteinsGlutathione S-transferaseEndocrinologyOncologybiology.protein570 Life sciences; biologyFemale2730 OncologyOvarian cancerCancer Letters
researchProduct

Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma

1997

Peptides derived from melanocyte differentiation antigens have been identified as targets for MHC class I-restricted cytolytic T lymphocytes (CTLs) in human melanoma Regression of antigen-expressing tumors as well as selection of antigen-loss variants in the presence of antigen-specific CTLs have previously been reported. In the present study, we determined the expression of the melanocyte differentiation antigens Melan A/MART-1 and tyrosinase by mRNA analysis and by immunohistochemical staining with the monoclonal antibodies (MAbs) A103 and T311. Co-expression of Melan A/MART-1 and tyrosinase was detected by both methods in 18/20 melanomas tested. However, immunohistochemistry provided add…

AdultMaleCancer ResearchSkin Neoplasmsmedicine.drug_classBiopsyGenes MHC Class I10050 Institute of Pharmacology and Toxicology610 Medicine & healthMonoclonal antibodyPolymerase Chain ReactionMART-1 AntigenMelanocyte differentiationAntigenAntigens NeoplasmMHC class IHLA-A2 AntigenmedicineHumans1306 Cancer ResearchRNA MessengerMelanomaAgedDNA PrimersAged 80 and overbiologyMonophenol MonooxygenaseLiver NeoplasmsMiddle AgedImmunohistochemistryNeoplasm ProteinsCytolysisCTL*OncologyTumor progressionLymphatic MetastasisImmunologyCancer researchbiology.proteinImmunohistochemistry570 Life sciences; biologyFemale2730 Oncology
researchProduct

Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndrome…

2008

Somatostatin-producing neuroendocrine tumors (SOM-NETs) of the duodenum and pancreas appear to be heterogeneous. To determine their clinicopathological profiles, respective data were analyzed on a series of 82 duodenal and 541 pancreatic NETs. In addition, the clinical records of 821 patients with duodenal or pancreatic NETs were reviewed for evidence of a somatostatinoma syndrome. Predominant or exclusive expression of somatostatin was found in 21 (26%) duodenal and 21 (4%) pancreatic NETs. They were classified as sporadic (n=31) or neurofibromatosis type 1 (NF1)-associated duodenal NETs (n=3), gangliocytic paragangliomas (GCPGs; n=6), or poorly differentiated neuroendocrine carcinomas (pd…

AdultMaleCancer Researchmedicine.medical_specialtyEndocrinology Diabetes and Metabolism610 Medicine & healthNeuroendocrine tumorsGastroenterologyParagangliomaEndocrinologyDuodenal NeoplasmsInternal medicine10049 Institute of Pathology and Molecular PathologySomatostatinomaMultiple Endocrine Neoplasia Type 1MedicineHumansMEN11306 Cancer ResearchGenetic Predisposition to DiseaseNeurofibromatosisMultiple endocrine neoplasia610 Medicine & healthAgedAged 80 and overbusiness.industryIncidenceSyndromeSomatostatinomaMiddle Agedmedicine.diseasePrognosis1310 EndocrinologyPancreatic Neoplasms2712 Endocrinology Diabetes and MetabolismNeuroendocrine Tumorsmedicine.anatomical_structureSomatostatinOncologyDuodenum570 Life sciences; biology2730 OncologyFemalebusinessPancreasSomatostatinFollow-Up Studies
researchProduct

Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology P…

2014

Purpose The prevalence of anaplastic lymphoma kinase (ALK) gene fusion (ALK positivity) in early-stage non–small-cell lung cancer (NSCLC) varies by population examined and detection method used. The Lungscape ALK project was designed to address the prevalence and prognostic impact of ALK positivity in resected lung adenocarcinoma in a primarily European population. Methods Analysis of ALK status was performed by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) in tissue sections of 1,281 patients with adenocarcinoma in the European Thoracic Oncology Platform Lungscape iBiobank. Positive patients were matched with negative patients in a 1:2 ratio, both for IHC and for …

AdultMaleCancer Researchmedicine.medical_specialtyPathologyLung NeoplasmsPopulation610 Medicine & healthAdenocarcinoma of LungAdenocarcinomaGastroenterologyCohort Studies10049 Institute of Pathology and Molecular Pathologyhemic and lymphatic diseasesThoracic OncologyInternal medicinePrevalencemedicineHumansAnaplastic lymphoma kinase1306 Cancer ResearchAnaplastic Lymphoma KinaseLung cancereducationIn Situ Hybridization FluorescenceAgedNeoplasm Stagingeducation.field_of_studyLungbusiness.industryALK-PositiveReceptor Protein-Tyrosine KinasesMiddle Agedmedicine.diseaseImmunohistochemistryEuropeTreatment Outcomemedicine.anatomical_structureOncology10032 Clinic for Oncology and HematologyImmunohistochemistryAdenocarcinoma2730 OncologyFemalebusiness
researchProduct

Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptidesin vivo: Implications for tumor vaccines with melanoma-associated…

1996

Peptide epitopes derived from differentiation antigens of the melanocyte lineage have been identified in human melanomas and normal cultured melanocytes as targets for MHC-restricted cytotoxic T lymphocytes (CTL). Characterization of multiple CTL-defined antigenic determinants and the presence of corresponding precursor CTL open perspectives for the development of antigen-based vaccines. In the present study, we determined the CTL reactivity against melanoma-associated peptides derived from Melan A/MART-1, tyrosinase and gp100/Pmel17 in 10 HLA-A2+ melanoma patients and 10 healthy individuals. Then, we examined the immunological effects and toxicity of intradermal inoculation of synthetic me…

AdultMaleSignal peptideCancer ResearchInjections IntradermalMolecular Sequence DataTyrosinase Peptide10050 Institute of Pharmacology and Toxicology610 Medicine & healthchemical and pharmacologic phenomenaPeptideEpitopeImmune systemAntigenAntigens NeoplasmHumansCytotoxic T cellMedicine1306 Cancer ResearchHypersensitivity DelayedAmino Acid SequenceMelanomaCells CulturedAgedchemistry.chemical_classificationVaccinesbusiness.industryMiddle AgedNeoplasm ProteinsCTL*OncologychemistryImmunology570 Life sciences; biology2730 OncologyFemalebusinessMelanoma-Specific AntigensT-Lymphocytes CytotoxicInternational Journal of Cancer
researchProduct